Nuveen
FULC icon

Nuveen’s Fulcrum Therapeutics FULC Stock Holding History

Nuveen’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Buy
154,871
+25,253
+19% +$154K ﹤0.01% 3216
2026
Q1 		$994K Buy
129,618
+17,415
+16% +$162K ﹤0.01% 2583
2025
Q4 		$1.27M Hold
112,203
– – ﹤0.01% 2496
2025
Q3 		$1.03M Sell
112,203
-12,520
-10% -$90.6K ﹤0.01% 2611
2025
Q2 		$858K Sell
124,723
-28,269
-18% -$151K ﹤0.01% 2678
2025
Q1 		$441K Sell
152,992
-16,557
-10% -$60.8K ﹤0.01% 2946
2024
Q4 		$797K Hold
169,549
– – ﹤0.01% 2805
2024
Q3 		$605K Hold
169,549
– – ﹤0.01% 2947
2024
Q2 		$1.05M Buy
+169,549
New +$1.28M ﹤0.01% 2706
2023
Q2 		– Sell
-288,737
Closed -$823K – 3239
2023
Q1 		$823K Buy
288,737
+35,012
+14% +$314K ﹤0.01% 2674
2022
Q4 		$1.85M Buy
253,725
+95,519
+60% +$623K ﹤0.01% 2424
2022
Q3 		$1.28M Sell
158,206
-242,936
-61% -$1.74M ﹤0.01% 2634
2022
Q2 		$1.97M Buy
401,142
+109,810
+38% +$1.07M ﹤0.01% 2442
2022
Q1 		$4.97M Sell
291,332
-88,314
-23% -$1.25M ﹤0.01% 2063
2021
Q4 		$5.97M Buy
379,646
+247,768
+188% +$4.91M ﹤0.01% 2021
2021
Q3 		$4.07M Buy
131,878
+15,847
+14% +$300K ﹤0.01% 2323
2021
Q2 		$1.22M Sell
116,031
-27,171
-19% -$275K ﹤0.01% 2938
2021
Q1 		$1.69M Buy
143,202
+25,448
+22% +$315K ﹤0.01% 2695
2020
Q4 		$1.38M Buy
117,754
+67,598
+135% +$764K ﹤0.01% 2678
2020
Q3 		$397K Buy
50,156
+794
+2% +$9.56K ﹤0.01% 3011
2020
Q2 		$902K Buy
49,362
+13,532
+38% +$213K ﹤0.01% 2659
2020
Q1 		$428K Buy
+35,830
New +$573K ﹤0.01% 2822

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's FULC Position: Q2 2026 in Review

Nuveen increased its Fulcrum Therapeutics (FULC) stake by 19% in Q2 2026, buying an estimated $154K and bringing the position to 154,871 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

Nuveen first reported a position in FULC in Q1 2020 and has held it in 22 quarters since. The position peaked at $5.97M in Q4 2021. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Nuveen held 154,871 shares of Fulcrum Therapeutics worth $567K as of Q2 2026.
  • Nuveen bought 25,253 Fulcrum Therapeutics shares in Q2 2026, an estimated $154K.
  • Fulcrum Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3216 holding.
  • Nuveen first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • Nuveen's Fulcrum Therapeutics position peaked at $5.97M in Q4 2021.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.